Many new drugs require innovative devices such as autoinjectors for drug delivery. Medical device developer SHL Group discusses how to plan their development.
Looking at self-administration therapy trends, injectable drug delivery devices such as pen injectors, autoinjectors and needle-free injectors show significant growth potential. It is estimated that the market for pen systems and autoinjectors will reach US$870m (€654m) in 2013 and $1.07bn (€804m) in 2015.1 Industry analysts estimate that more than 30% of all new product submissions to the FDA are combination products.2 Among these, the autoinjector is one of the fastest emerging drug delivery solutions.
While the autoinjector is now considered commercially suitable for the delivery of therapeutic drugs, to develop such a device successfully requires detailed planning, combination product knowledge, regulatory awareness and close collaboration with a carefully chosen device manufacturer.
An autoinjector consists of a pre-filled syringe (PFS) or cartridge inside a device that applies enough force to inject fully the desired drug within the specified requirements. Both of these components are regulated and together define the autoinjector as a combination product.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.